Abdom Radiol (NY)

1. QIN S, Luo H, Hong Y, Fu C, et al
   Evaluation of T1 and T2 mapping for non-invasive assessment of HER2 and PD-L1 expression in bladder cancer.
   Abdom Radiol (NY). 2026 Mar 9. doi: 10.1007/s00261-026-05390.
   

   >> Share

   
   
2. TUCKER J, Sharma V, Johnson M, Hibbert R, et al
   Safety and Diagnostic Yield of Percutaneous Urinary Bladder Tumor Biopsy.
   Abdom Radiol (NY). 2026;51:1444-1449.
   

   >> Share

   
   

   
   ACS Nano

3. GAO Y, Yang F, Yin L, Wang W, et al
   A Redox-Responsive Selenium-Containing Nanomedicine Enables Dual Antioxidant System Inhibition to Overcome Platinum Resistance and Enhance Immunotherapy in Bladder Cancer.
   ACS Nano. 2026 Mar 10. doi: 10.1021/acsnano.5c21831.
   

   >> Share

   
   

   
   Adv Mater

4. SU Y, Wu J, Deng Z, Luo Y, et al
   In Vivo Target Drug Enrichment Based on Spatiotemporal Acoustic Node Modulation (STANM) for Bladder Cancer Treatment.
   Adv Mater. 2026 Mar 10:e17740. doi: 10.1002/adma.202517740.
   

   >> Share

   
   

   
   Aging (Albany NY)

5. GONG Z, He Y, Mi X, Li C, et al
   Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer.
   Aging (Albany NY). 2023;15:9479-9498.
   

   >> Share

   
   

   
   Anal Chem

6. ZHANG J, Guo F, Zhu J, He Z, et al
   Ultrasensitive Electrochemiluminescence Immunosensor for Bladder Marker Human Complement Factor H-Related Protein Detection.
   Anal Chem. 2023;95:11440-11448.
   

   >> Share

   
   

   
   Ann Surg Oncol

7. SRETENOVIC M, Bumbasirevic U, Bojanic N, Durutovic O, et al
   Prognostic Value of Preoperative Anemia on Survival and Recurrence in Patients with Bladder Carcinoma Treated by Radical Cystectomy.
   Ann Surg Oncol. 2026;33:3743-3751.
   

   >> Share

   
   
8. WANG Y, Wu N, Zhang F, Zhang S, et al
   The Comprehensive Complication Index for Assessing Short-Term Complications of Urothelial Carcinoma with Variant Histology: A Patient-Based Study.
   Ann Surg Oncol. 2026;33:3688-3697.
   

   >> Share

   
   
9. LONGONI M, Le QC, Falkenbach F, Marmiroli A, et al
   The Effect of Pelvic Lymph Node Dissection on Cancer-Specific Mortality in Partial Cystectomy According to Eligibility Criteria.
   Ann Surg Oncol. 2026;33:3680-3687.
   

   >> Share

   
   

   
   Arch Esp Urol

10. AKIN Y, Yorulmaz EM, Gorgel SN, Ozcan S, et al
    Who is Next? Impact of Systemic Immune-Inflammation Index and De Ritis Ratio for Predicting 90-Day Survival after Salvage Cystectomy in Advanced Bladder Cancer.
    Arch Esp Urol. 2026;79:66-72.
    

    >> Share

    
    
11. SARI H, Celik S, Yorukoglu K, Celebi I, et al
    Ankaferd versus Immunotherapeutics and Chemotherapeutics in Bladder Cancer.
    Arch Esp Urol. 2026;79:58-65.
    

    >> Share

    
    

    
    Asian J Pharm Sci

12. FAN G, Luo X, Li K, Zhang Z, et al
    Development and preclinical evaluation of a novel FGFR3-targeted antibody-drug conjugate in bladder cancer.
    Asian J Pharm Sci. 2025;20:101095.
    

    >> Share

    
    

    
    Asian J Urol

13. LIU W, Xiao J, Zou J, He Z, et al
    Recurrence and prevention strategies for non-muscle-invasive bladder cancer: A comprehensive review.
    Asian J Urol. 2026;13:11-23.
    

    >> Share

    
    

    
    Asian Pac J Cancer Prev

14. NUR BUDAYA T, Seputra KP, Susianti H, Aditya Hutama S, et al
    Diagnostic Value of Rabbit-Derived 47 kDa Epitope-Based Antibodies as a Detection and Evaluation Method for Bladder Cancer.
    Asian Pac J Cancer Prev. 2026;27:911-920.
    

    >> Share

    
    

    
    Biochem Biophys Res Commun

15. ANDO K, Kurashina R, Motoi N, Iizuka T, et al
    Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma.
    Biochem Biophys Res Commun. 2023;676:165-170.
    

    >> Share

    
    

    
    Biochim Biophys Acta Mol Basis Dis

16. ZHANG Q, Hong Y, He C, Guo R, et al
    Oncogenic epigenetic factor EP300 is a potential therapeutic target for bladder carcinoma.
    Biochim Biophys Acta Mol Basis Dis. 2026;1872:168182.
    

    >> Share

    
    

    
    Biosens Bioelectron

17. ZHANG Y, Liu L, Yang B, Wu Q, et al
    Electron transfer-driven ultrathin nanozyme synergizes with nucleic acid amplification for bladder cancer screening.
    Biosens Bioelectron. 2026;303:118580.
    

    >> Share

    
    

    
    BJU Int

18. BRYAN RT, Patel K, Ward DG
    The nascent role of circulating tumour DNA in the management of non-muscle-invasive bladder cancer.
    BJU Int. 2026 Mar 3. doi: 10.1111/bju.70217.
    

    >> Share

    
    
19. FERNANDEZ-MARDOMINGO A, Subiela JD, Artiles Medina A, Krajewski W, et al
    Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groups.
    BJU Int. 2026 Mar 3. doi: 10.1111/bju.70207.
    

    >> Share

    
    
20. DAY E, Bizzarri FP, Waine E, Martin R, et al
    Contemporary practice patterns in female radical cystectomy: results of a UK and Ireland survey.
    BJU Int. 2026;137:708-715.
    

    >> Share

    
    
21. PIAZZA P, Barretta A, Bravi CA, Mottaran A, et al
    Impact of cumulative smoking exposure on morbidity after robot-assisted radical cystectomy.
    BJU Int. 2026;137:684-689.
    

    >> Share

    
    

    
    BJUI Compass

22. ISTAMULOV M, Eriksson H, Abuhasanein S
    Standardized care pathway reshaped the diagnostic and therapeutic landscape of urinary bladder cancer. A 15-year population-based study.
    BJUI Compass. 2026;7:e70179.
    

    >> Share

    
    

    
    Bladder Cancer

23. MALSHY K, Messing EM
    Circulating tumor DNA-guided adjuvant immunotherapy in muscle-invasive bladder cancer.
    Bladder Cancer. 2026;12:23523735261429862.
    

    >> Share

    
    
24. SUPERDOCK M, Wobker SE, Carmicheal I, Kim WY, et al
    Computational pathology in bladder cancer: A scoping review.
    Bladder Cancer. 2026;12:23523735251413333.
    

    >> Share

    
    

    
    BMC Cancer

25. GAO WB, Yu JJ
    Celldetect test performance in monitoring bladder cancer recurrence after transurethral resection.
    BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15797.
    

    >> Share

    
    

    
    BMJ Case Rep

26. PRIETO MATIENZO L, Fischer-Straub A, Perera M, Babst C, et al
    Follicular lymphoma of the urachus.
    BMJ Case Rep. 2026;19:e267211.
    

    >> Share

    
    

    
    Can J Urol

27. DONMEZ K, Yorulmaz EM, Candemir E, Ozcan S, et al
    Unusual metastatic patterns of urologic malignancies: a case series and literature review.
    Can J Urol. 2026;33:211-219.
    

    >> Share

    
    
28. AKKAD A, Bruyere F, Bourgi A
    Uretero-enteric strictures after cystectomy: revealing the modifiable risk factors.
    Can J Urol. 2026;33:155-163.
    

    >> Share

    
    
29. ZHAN M, Zhou Z, Zhang J, Wang X, et al
    Artificial intelligence in urological malignancy diagnosis and prognosis: current status and future prospects.
    Can J Urol. 2026;33:35-49.
    

    >> Share

    
    

    
    Cancer Cell

30. CHEN C, An M, Zheng H, Pang M, et al
    B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity.
    Cancer Cell. 2026;44:551-566.
    

    >> Share

    
    

    
    Cancer Cell Int

31. LI P, Li L, Li Z, Wang S, et al
    Correction: Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway.
    Cancer Cell Int. 2026;26:119.
    

    >> Share

    
    

    
    Cancer Discov

32. 
    Strategy to Analyze Urine Tumor DNA Predicts Outcomes in Bladder Cancer.
    Cancer Discov. 2026 Feb 11:OF1. doi: 10.1158/2159-8290.CD-RW2026.
    

    >> Share

    
    

    
    Cancer Genomics Proteomics

33. BARLAK BSR, Iskender B
    Proteomic Signatures of Cellular Reprogramming in Bladder Cancer: Insights into the Acquisition of Cancer Stem-like States and Phenotypic Plasticity.
    Cancer Genomics Proteomics. 2026;23:300-321.
    

    >> Share

    
    

    
    Cancer Immunol Immunother

34. JIANG Y, Li J, Yang Z, Ma M, et al
    Multi-omics study on tumor-associated macrophages remodeling the tumor microenvironment via the CXCL5-CXCR2 axis to drive immune escape in bladder cancer.
    Cancer Immunol Immunother. 2026;75:103.
    

    >> Share

    
    

    
    Cancer Manag Res

35. WANG Q, Pei CS, Cao JY, Peng H, et al
    Impact of Surgical Wait Time on Survival After Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.
    Cancer Manag Res. 2026;18:583762.
    

    >> Share

    
    

    
    Cancer Med

36. MANCIN S, Ferrara G, Palomares SM, Matteucci S, et al
    Vitamin D and Bladder Cancer Risk: An Umbrella Review and Second Order Meta-Analysis.
    Cancer Med. 2026;15:e71672.
    

    >> Share

    
    

    
    Cancer Res

37. GARCIA-RODRIGUEZ JL, Korsgaard U, Ahmadov U, Jarlstad Olesen MT, et al
    Spatial Profiling of Circular RNAs in Cancer Reveals High Expression in Muscle and Stromal Cells.
    Cancer Res. 2023;83:3340-3353.
    

    >> Share

    
    

    
    Cancer Sci

38. TIAN X, Liu Y, Mi Z, Liang Y, et al
    CALR/HIF-1alpha Positive Feedback Loop Drives CALR Upregulation to Promote EMT-Mediated Bladder Cancer Progression via ROS/AKT Axis.
    Cancer Sci. 2026 Mar 5. doi: 10.1111/cas.70354.
    

    >> Share

    
    

    
    Cell Signal

39. GUO X, Zhu C, Yin Z
    A positive SPTBN2-FLI1 feedback axis promotes bladder cancer via PI3K/AKT activation.
    Cell Signal. 2026 Mar 4:112471. doi: 10.1016/j.cellsig.2026.112471.
    

    >> Share

    
    

    
    Clin Chim Acta

40. KHAN A, Alanazi FJ, Ahmed S, Alzahrani AR, et al
    Glycoprotein biomarkers for bladder cancer detection.
    Clin Chim Acta. 2026;586:120938.
    

    >> Share

    
    

    
    Clin Exp Med

41. AJALLI MM, Sansebli Y, Ekrami D, Alaeenejad F, et al
    Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to emerging combination frontlines.
    Clin Exp Med. 2026 Mar 5. doi: 10.1007/s10238-026-02098.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

42. DOMANSKI P, Hanusz K, Zapala L, Shah P, et al
    Efficacy and Safety of Intravesical Gemcitabine and Docetaxel Combination Therapy in Patients With Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Clin Genitourin Cancer. 2026 Feb 11:102514. doi: 10.1016/j.clgc.2026.102514.
    

    >> Share

    
    

    
    Clin Nucl Med

43. MAN X, Dong C, Dong A, Song X, et al
    FDG PET/CT in Primary Mucosa-associated Lymphoid Tissue Lymphoma of the Bladder.
    Clin Nucl Med. 2026 Jan 6. doi: 10.1097/RLU.0000000000006295.
    

    >> Share

    
    

    
    Clin Transl Med

44. VAN CREIJ NCH, Tymoszuk P, Handle F, Seeber A, et al
    Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy.
    Clin Transl Med. 2026;16:e70638.
    

    >> Share

    
    

    
    Crit Rev Oncol Hematol

45. XU C, Zou W, Wang Y, Liu X, et al
    Bladder-sparing treatment for muscle-invasive bladder carcinoma using immune checkpoint inhibitors.
    Crit Rev Oncol Hematol. 2023;191:104137.
    

    >> Share

    
    

    
    Cureus

46. MIYAMOTO T, Miyake M, Nishimura N, Oda Y, et al
    Immunogenic Tumor Cell Death Induced by Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer: An Immunohistochemical Analysis.
    Cureus. 2026;18:e102672.
    

    >> Share

    
    

    
    Curr Oncol

47. HUANG J, Ojo A, Liaw B
    Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma.
    Curr Oncol. 2026;33:103.
    

    >> Share

    
    

    
    Curr Opin Urol

48. GONZALEZ-PADILLA DA, Subiela JD, Guerrero-Ramos F, Pichler R, et al
    Latest developments in urinary tumor DNA and its current clinical role in urothelial bladder cancer and upper tract urothelial carcinoma.
    Curr Opin Urol. 2026 Mar 4. doi: 10.1097/MOU.0000000000001373.
    

    >> Share

    
    

    
    Curr Probl Diagn Radiol

49. PERUZZI V, Torresan S, Cortiula F, Fanelli M, et al
    Unveiling the Potential of Venn Diagrams as a Helpful Tool for Clinical Reasoning: An Illustrative Case-based Discussion.
    Curr Probl Diagn Radiol. 2023;52:478-481.
    

    >> Share

    
    

    
    Diagn Cytopathol

50. ORDOBAZARI A, Nikfar R, Zhao X, Davaro E, et al
    Evaluating the Performance of the Paris System in Neobladder Cytology: The Role of Cellularity and Volume Adequacy Criteria.
    Diagn Cytopathol. 2026;54:299-306.
    

    >> Share

    
    
51. FARTIYAL JS, Rao M, Elhence PA, Nalwa A, et al
    Comparison of Conventional Sediment Smears and Liquid-Based Cytology and Utility of Cell Block Preparation in Urinary Cytology.
    Diagn Cytopathol. 2026;54:285-292.
    

    >> Share

    
    

    
    Dis Markers

52. 
    Correction to "KIF20A Affects the Prognosis of Bladder Cancer by Promoting the Proliferation and Metastasis of Bladder Cancer Cells".
    Dis Markers. 2026;2026:9804137.
    

    >> Share

    
    

    
    Discov Oncol

53. CAO JY, Peng H, Wang GY, Chang PA, et al
    IGF2BP3 promotes the muscle invasion of bladder cancer via PPARgamma dysregulation.
    Discov Oncol. 2026 Mar 5. doi: 10.1007/s12672-026-04648.
    

    >> Share

    
    

    
    Eur J Med Chem

54. ZHANG M, Wang K, Li G, Bao X, et al
    Light-activated targeted degradation of VHL drug for selective tumor killing: A novel strategy for precision therapy of bladder cancer.
    Eur J Med Chem. 2026;309:118736.
    

    >> Share

    
    

    
    Eur Radiol

55. WOO S, Luk L, Muglia VF, Briganti A, et al
    VI-RADS quality score: development and proposal of a scoring system by the American College of Radiology VI-RADS Steering Committee.
    Eur Radiol. 2026;36:1093-1104.
    

    >> Share

    
    

    
    Eur Urol Oncol

56. LIJNEN RAG, Ringia JB, Claps F, Vogel WV, et al
    Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer.
    Eur Urol Oncol. 2026 Mar 6:S2588-9311(26)00046-5. doi: 10.1016/j.euo.2026.
    

    >> Share

    
    
57. THU PHUNG TA, Weng R, Black PC, Dyrskjot L, et al
    A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity.
    Eur Urol Oncol. 2026 Feb 27:S2588-9311(26)00057.
    

    >> Share

    
    

    
    Expert Rev Anticancer Ther

58. D'AGOSTINO E, Pirola M, Callegari V, Tonni E, et al
    Future directions for antibody-drug conjugates in urothelial cancer.
    Expert Rev Anticancer Ther. 2026;26:321-332.
    

    >> Share

    
    
59. KEANE KG, Redfern A, Lim J, Hayne D, et al
    The role of gemcitabine-docetaxel in the management of NMIBC: a scoping review of current status and future directions.
    Expert Rev Anticancer Ther. 2026;26:333-344.
    

    >> Share

    
    
60. KEANE KG, Redfern A, Lim J, Hayne D, et al
    The role of immune checkpoint inhibitors in the management of NMIBC: a scoping review of current status and future direction.
    Expert Rev Anticancer Ther. 2026;26:307-320.
    

    >> Share

    
    

    
    Folia Med (Plovdiv)

61. OEY O, Tiong SS, Wong SL, Navadgi S, et al
    Triple synchronous malignancies of the stomach, bladder and thyroid in a previously treated prostate cancer patient: A Case Report.
    Folia Med (Plovdiv). 2023;65:693-698.
    

    >> Share

    
    

    
    Fr J Urol

62. TANGUY M, Armelle P, Sheik E, Nicolas I, et al
    Real-World Data on Neoadjuvant Chemotherapy for Localized Muscle-Invasive Bladder Cancer (2015-2024): A Single-Center Retrospective Study.
    Fr J Urol. 2026 Mar 3:103093. doi: 10.1016/j.fjurol.2026.103093.
    

    >> Share

    
    
63. FORTIER A, Mokadem S, Saadi A, Gillibert A, et al
    Does ureteroileal anastomosis technique (Bricker versus Wallace) influence benign ureteroileal stricture occurrence on transileal diversion?
    Fr J Urol. 2026;36:103078.
    

    >> Share

    
    

    
    Front Cell Infect Microbiol

64. QI T, Yang W, Liu R, Deng D, et al
    SWI/SNF-associated molecular subtypes reshape tumor microenvironmental features and inform precision therapeutic strategies in bladder cancer.
    Front Cell Infect Microbiol. 2026;16:1774929.
    

    >> Share

    
    

    
    Front Endocrinol (Lausanne)

65. WANG X, Zhao J, Li Q, Chang J, et al
    Disulfidptosis and androgenic cancers: from molecular mechanisms to clinical applications and future translational research.
    Front Endocrinol (Lausanne). 2026;17:1783929.
    

    >> Share

    
    

    
    Front Immunol

66. CERBONE L, Roviello G, Calabro F, Taha T, et al
    Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
    Front Immunol. 2026;17:1667155.
    

    >> Share

    
    

    
    Front Oncol

67. TAN K, Quan X, Tan M, Han Z, et al
    Metachronous multiple primary cancers involving pulmonary non-Hodgkin lymphoma and bladder cancer: a case report.
    Front Oncol. 2026;16:1734661.
    

    >> Share

    
    
68. LI Z, Wang G, Tan S, Wang Y, et al
    Expression of ribosomal S6 kinase 4 in bladder cancer and its correlation with clinicopathological features.
    Front Oncol. 2026;16:1757293.
    

    >> Share

    
    
69. FENG R, Zhang J, Tao Y, Hou J, et al
    Correction: Preoperative inflammation-based immune prognostic nomogram in bladder cancer: a multicenter study.
    Front Oncol. 2026;16:1787982.
    

    >> Share

    
    
70. BLUMENFELD P, Levy D, Hillman Y, Feldman J, et al
    Daily artificial intelligence-assisted adaptive small margin radiotherapy during trimodal therapy of muscle-invasive bladder cancer.
    Front Oncol. 2026;16:1729810.
    

    >> Share

    
    

    
    Future Med Chem

71. WEI G, Fan ZH, Huang RZ, Wei Y, et al
    Design, synthesis and antitumor activity evaluation of 1,4-naphthoquinone-benzene sulfonamide hybrids.
    Future Med Chem. 2026;18:637-648.
    

    >> Share

    
    

    
    Hum Pathol

72. COLLINS K, Gupta S, Cheng L
    Updates in bladder and prostate pathology: Diagnostic consensus and clinical relevance.
    Hum Pathol. 2026;169:106018.
    

    >> Share

    
    

    
    IJU Case Rep

73. ITO K, Yamashita R, Kasai S, Sakura Y, et al
    A Case of Unexpected Peritoneal Carcinomatosis From Colon Cancer Detected After Robot-Assisted Radical Cystectomy for Advanced Bladder Cancer.
    IJU Case Rep. 2026;9:e70155.
    

    >> Share

    
    
74. IMAI K, Masuda N, Hazama T, Hosomi T, et al
    Invasive Bladder Cancer With Peritoneal Invasion and Rectal Involvement Causing Rectal, Bilateral Ureteral, and Common Bile Duct Obstruction Without a Retroperitoneal Mass: A Case Report.
    IJU Case Rep. 2026;9:e70157.
    

    >> Share

    
    

    
    Int Immunopharmacol

75. GAO X, Liu J, Deng D, Xiao J, et al
    The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer.
    Int Immunopharmacol. 2026;175:116443.
    

    >> Share

    
    

    
    Int J Med Sci

76. HUANG Z, Cao X, Yan Y, Li H, et al
    Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation.
    Int J Med Sci. 2026;23:986-1001.
    

    >> Share

    
    

    
    Int J Surg Pathol

77. RIZKALLA CN, Tretiakova M, Williamson SR, Akgul M, et al
    Overlapping Morphologic and Immunophenotypic Features of Plasmacytoid Urothelial Carcinoma and Urothelial Carcinoma With Osteoclast-Like Giant Cells.
    Int J Surg Pathol. 2026;34:309-314.
    

    >> Share

    
    

    
    Int Urol Nephrol

78. ZHENG Q, Liao E, Chen D, Shan G, et al
    Bladder cancer organoids: bridging pathological features and drug response for precision oncology.
    Int Urol Nephrol. 2026 Mar 8. doi: 10.1007/s11255-026-05081.
    

    >> Share

    
    
79. THAKKER PU, Refugia JM, Casals R, Able C, et al
    Stent-free rates in cutaneous ureterostomy urinary diversion after radical cystectomy.
    Int Urol Nephrol. 2023;55:2809-2814.
    

    >> Share

    
    

    
    Investig Clin Urol

80. KUROBE M, Ogawa T, Satoh Y, Yamamoto M, et al
    Near infrared ray-guided partial cystectomy using da Vinci Firefly((R)) technology and intraoperative cystoscopy for urachal cyst, suspected of urachal tumor.
    Investig Clin Urol. 2026;67:178-185.
    

    >> Share

    
    
81. YOON SG, Park TY, Jin HJ, Noh TI, et al
    Long-term oncologic outcomes of robot-assisted radical cystectomy: Prognostic indicators and complication profiles from a high-volume single-surgeon series.
    Investig Clin Urol. 2026;67:148-161.
    

    >> Share

    
    
82. CHOI SY, Yang YJ, Min KC, Lee YS, et al
    Diagnostic performance of narrow-band imaging and photodynamic diagnosis compared to white light cystoscopy for non-muscle invasive bladder cancer: A network meta-analysis of randomized trials.
    Investig Clin Urol. 2026;67:131-139.
    

    >> Share

    
    

    
    J Biochem Mol Toxicol

83. LU S, Zhang X, Cai Z, Xi Z, et al
    Identification of novel lncRNA prognostic biomarkers and their associated ceRNAs in bladder urothelial carcinoma.
    J Biochem Mol Toxicol. 2023;37:e23441.
    

    >> Share

    
    

    
    J Cancer Policy

84. BENCINA G, Ruiz RA, Bencina B
    Evaluating the economic burden of bladder cancer in 32 European countries using a value of a statistical life year framework.
    J Cancer Policy. 2026;48:100728.
    

    >> Share

    
    

    
    J Clin Invest

85. MEEKS JJ
    The changing landscape of urothelial carcinoma: on the edge of a paradigm shift.
    J Clin Invest. 2026;136:e202079.
    

    >> Share

    
    

    
    J Clin Oncol

86. KAMAT AM, Hensley PJ, Maiorano BA, Li R, et al
    Bacillus Calmette-Guerin (BCG) and Beyond: Is Systemic Immunotherapy for BCG-Naive Non-Muscle-Invasive Bladder Cancer Progress or Overreach?
    J Clin Oncol. 2026 Mar 2:JCO2502670. doi: 10.1200/JCO-25-02670.
    

    >> Share

    
    

    
    J Coll Physicians Surg Pak

87. LI J, He Y, Wu S
    Predictors of Residual Tumour in Non-Muscle-Invasive Bladder Cancer Following Repeat Transurethral Resection: A Meta-Analysis.
    J Coll Physicians Surg Pak. 2026;36:87-94.
    

    >> Share

    
    

    
    J Racial Ethn Health Disparities

88. DENG Z, Li M, Li J, Jung M, et al
    Disparities in Cancer and Cardiovascular Disease Mortality Among Asian Americans Diagnosed with Urologic Cancer.
    J Racial Ethn Health Disparities. 2026;13:1555-1571.
    

    >> Share

    
    

    
    J Surg Oncol

89. MENGYAN J, Jun Q, Wen L, Tingting P, et al
    Research Progress on Financial Toxicity in Bladder Cancer Patients.
    J Surg Oncol. 2026 Mar 8. doi: 10.1002/jso.70201.
    

    >> Share

    
    

    
    J Urol

90. UDEDIBIA E, Solosky K, Macdonald EJ, Gaines J, et al
    Critical Analysis of the AUA 2020/2025 Microscopic Hematuria Guidelines to Predict Urothelial but Not Renal Cortical Neoplasms and Validation of the Individual Clinical Components in Risk Stratification for Urothelial Neoplasms but Not Renal Cortical
    J Urol. 2026;215:441-449.
    

    >> Share

    
    

    
    J Vet Intern Med

91. BURTZ M, Boss MK, Leary D, Martin TW, et al
    Radiation therapy as a treatment for urinary obstruction secondary to urothelial carcinoma in dogs.
    J Vet Intern Med. 2026;40:aalaf093.
    

    >> Share

    
    

    
    JCO Oncol Pract

92. WONG R, Matulewicz RS, Talwar R, Goldstein AO, et al
    Temporal Association of US Tobacco Taxation on Smoking Attributable Bladder Cancer Mortality and Disability-Adjusted Life Years.
    JCO Oncol Pract. 2026 Mar 2:OP2500780. doi: 10.1200/OP-25-00780.
    

    >> Share

    
    

    
    Jpn J Clin Oncol

93. YAMASHITA S, Wada T, Deguchi R, Mashima N, et al
    Prognostic significance of pre-treatment albumin-bilirubin grade in metastatic urothelial carcinoma receiving pembrolizumab.
    Jpn J Clin Oncol. 2023;53:845-850.
    

    >> Share

    
    

    
    Lancet Oncol

94. NECCHI A, Maiorano BA, de Jong JJ, Proudfoot JA, et al
    Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study.
    Lancet Oncol. 2026 Feb 27:S1470-2045(26)00050.
    

    >> Share

    
    

    
    Magy Onkol

95. HERMANN-VARADI M
    [Prediction of immune checkpoint inhibitor therapy in urothelial carcinoma: integrated analysis of molecular patterns and clinical factors].
    Magy Onkol. 2026;70:85-87.
    

    >> Share

    
    
96. PULUGOR GD, Galdi A, Varga L, Jorgo K, et al
    [Daily online adaptive irradiation of bladder tumors with individualized safety margin creation].
    Magy Onkol. 2026;70:23-31.
    

    >> Share

    
    

    
    Mol Genet Genomics

97. HE J, Jiang Z, Peng S, Peng L, et al
    Single-cell transcriptomic profiling combined with Mendelian randomization illuminates molecular drivers of bladder cancer.
    Mol Genet Genomics. 2026;301:50.
    

    >> Share

    
    

    
    Nat Rev Clin Oncol

98. SIDAWAY P
    Enfortumab vedotin plus pembrolizumab effective in patients with resectable bladder cancer.
    Nat Rev Clin Oncol. 2026 Mar 2. doi: 10.1038/s41571-026-01139.
    

    >> Share

    
    

    
    NPJ Digit Med

99. HUANG J, Hu H, Sun M, Wu W, et al
    A domain-adaptive deep contrastive network for magnetic resonance imaging-driven bladder cancer classification.
    NPJ Digit Med. 2026 Mar 3. doi: 10.1038/s41746-026-02499.
    

    >> Share

    
    

    
    Pathol Res Pract

100. CUADRA JDP, Perez MA, Gonzalez-Peramato P, Sanz J, et al
     PD-L1 expression across urothelial carcinoma subtypes: A multicenter comparison of 22C3 and SP142 for clinical decision-making in the immunotherapy era.
     Pathol Res Pract. 2026;281:156372.
     

     >> Share

     
     

     
     Patient

101. MASON B, Eccleston A, Ayala-Nunes L, Hauber B, et al
     Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer.
     Patient. 2026 Mar 11. doi: 10.1007/s40271-026-00804.
     

     >> Share

     
     

     
     Pediatr Dev Pathol

102. KIMBALL J, Steele J, Vargas SO, Hirsch M, et al
     BK Polyomavirus-Associated Kidney and Bladder Carcinomas Following Heart and Lung Transplantation in Childhood.
     Pediatr Dev Pathol. 2026;29:128-135.
     

     >> Share

     
     

     
     PeerJ

103. NIE Q, Jiang M, Wan S, Xi M, et al
     Neuro-immune-related gene signatures define molecular subtypes and prognostic score in bladder cancer with SERPINE2 as a potential therapeutic target.
     PeerJ. 2026;14:e20917.
     

     >> Share

     
     

     
     Phytomedicine

104. SONG YS, Liu CK, Jiang WS, Liu J, et al
     Targeting GRB2 with Polyphyllin H overcomes PIKFYVE inhibitor resistance in bladder cancer by blocking Akt-SREBP1-SCD1 pathway.
     Phytomedicine. 2026;154:158011.
     

     >> Share

     
     

     
     Quant Imaging Med Surg

105. HAO Z, Zhu L, Ding J, Jin Q, et al
     bp-VI-RADS combined with normalized apparent diffusion coefficient enhances diagnostic efficacy for muscle-invasive bladder cancer.
     Quant Imaging Med Surg. 2026;16:244.
     

     >> Share

     
     

     
     Sci Rep

106. LI Z, Yu Y, Liu F, Wu Y, et al
     Suppression of LTBP1 enhances the sensitivity of bladder cancer to cisplatin.
     Sci Rep. 2026 Mar 13. doi: 10.1038/s41598-026-42815.
     

     >> Share

     
     
107. LODEWIJK I, Rubio C, Eriksson P, Reina IA, et al
     CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer.
     Sci Rep. 2026 Mar 11. doi: 10.1038/s41598-026-42566.
     

     >> Share

     
     
108. QIN Z, Zhou H, Hu Y, Xiong X, et al
     Survival prediction for bladder cancer using multimodal data with quantum neural networks and transformer architectures.
     Sci Rep. 2026 Mar 7. doi: 10.1038/s41598-026-42047.
     

     >> Share

     
     

     
     Se Pu

109. LIU S, Wang M, Wang W
     [Analysis of urine biomarkers in urothelial carcinoma based on untargeted metabolomics].
     Se Pu. 2026;44:329-337.
     

     >> Share

     
     

     
     Semin Nucl Med

110. MENA E, Lindenberg L, Heng S, Choyke PL, et al
     Advances and challenges of PET imaging in bladder cancer-An update and future trends.
     Semin Nucl Med. 2026 Mar 2:S0001-2998(26)00046.
     

     >> Share

     
     

     
     Surg Oncol

111. SONG SH, Park JH, Lee S, Jeong SH, et al
     Oncological outcomes of concurrent nephroureterectomy during radical cystectomy: A propensity score-matched analysis with multivariable adjustment from Korean multicenter database.
     Surg Oncol. 2026;65:102362.
     

     >> Share

     
     

     
     Toxicol Appl Pharmacol

112. YAN H, Yin C, Xu F, Li R, et al
     Unraveling the connection between PFOA and bladder cancer: A study integrating network toxicology, molecular docking, and experimental validation.
     Toxicol Appl Pharmacol. 2026;511:117784.
     

     >> Share

     
     

     
     Transl Androl Urol

113. LIANG S, Liu H, Su Q, Li X, et al
     Machine learning identifies a DNA repair-related risk model for bladder cancer and functionally characterizes ZWINT as a potential oncogenic factor.
     Transl Androl Urol. 2026;15:46.
     

     >> Share

     
     
114. LIU J, Tang X, Cui Y, Yang X, et al
     Development and validation of a gemcitabine sensitivity-related long noncoding RNA signature for predicting the prognosis and subtypes of bladder cancer.
     Transl Androl Urol. 2026;15:60.
     

     >> Share

     
     

     
     Urol Oncol

115. MOINARD-BUTOT F, Barbe-Richaud JB, Baudry E, Pierard L, et al
     Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder study.
     Urol Oncol. 2026;44:111036.
     

     >> Share

     
     

     
     Urologia

116. SHUKLA A, Hiralal, Raj H, Surekha S, et al
     Diagnostic accuracy and reliability of VI-RADS in assessing muscle invasion in bladder cancer: Insight from a prospective tertiary care study.
     Urologia. 2026 Mar 13:3915603261429445. doi: 10.1177/03915603261429445.
     

     >> Share

     
     

     
     Urologie

117. BOLENZ C, Heidenreich A
     [From limited options to individualized strategies: advances in the treatment of bladder cancer].
     Urologie. 2026;65:239-241.
     

     >> Share

     
     
118. GAISA NT, Reis H, Heidenreich A
     [Diagnosis and treatment of urothelial carcinoma of the bladder with divergent histology].
     Urologie. 2026;65:278-287.
     

     >> Share

     
     
119. KOHLER J, Rodler S, Andersson J, Juptner M, et al
     [Innovative imaging techniques for urothelial carcinoma].
     Urologie. 2026;65:242-249.
     

     >> Share

     
     
120. NIEGISCH G, Zschabitz S, Eckstein M, Klumper N, et al
     [From nontargeted to precision oncology: predictive biomarkers and targeted therapies in advanced urothelial carcinoma].
     Urologie. 2026;65:271-277.
     

     >> Share

     
     
121. SCHNEIDEWIND L, Kiss B, Arnold N, Kranz J, et al
     [Gender-specific differences in outcome and survival in early cystectomy : Systematic review].
     Urologie. 2026;65:300-307.
     

     >> Share

     
     
122. GIESE M, Butea-Bocu M, Huber J, Groeben C, et al
     [Prehabilitation prior to radical cystectomy].
     Urologie. 2023;62:1034-1040.
     

     >> Share

     
     
123. MENDES WEFELNBERG M, Reimer N, Baumann FT
     [Exercise therapy in prehabilitation : Current findings in urology].
     Urologie. 2023;62:1011-1016.
     

     >> Share

     
     

     
     World J Gastrointest Pharmacol Ther

124. WISHAHI M
     Gut microbiotas attributed to disorders and diseases of the gastrointestinal tract, colorectal cancer, bladder cancer: Geographical factors, inflammation, metabolic toxic.
     World J Gastrointest Pharmacol Ther. 2026;17:115573.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share